CPMD CANNAPHARMARX, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1081938 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-30.8%
TTM net income YoY-25.6%
TTM EPS YoY50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-114.1%
Operating margin-210.8%
Net margin-779.2%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-97.3%
ROIC (approx.)—
Asset turnover0.12x
Leverage & solvency
Liabilities / assets514.2%
Debt / equity—
Current ratio0.05x
Interest coverage-1.70x
Cash quality & payout
Operating cash flow / net income-0.06x
Accruals ratio-102.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $137,705 | $276,218 | $627,462 | $138,630 | $656,606 | $231,608 | $335,319 | $482,134 |
| Cost of revenue | $415,487 | $414,664 | $1.04M | $659,721 | $1.03M | $852,818 | $837,926 | $2.17M |
| Gross profit | -$277,782 | -$138,446 | -$409,453 | -$521,091 | -$373,707 | -$621,210 | -$502,607 | -$1.69M |
| SG&A expense | $159,445 | $82,739 | $35,814 | $229,604 | $211,737 | $75,952 | $38,641 | -$128,897 |
| Operating income | -$532,943 | -$378,831 | -$682,343 | -$893,553 | -$935,646 | -$840,980 | -$677,585 | -$1.53M |
| Interest expense | $458,291 | $349,008 | $475,617 | $179,423 | $506,331 | $657,515 | $615,516 | $322,210 |
| Pretax income | $645,416 | -$1.91M | — | — | -$1.48M | -$1.41M | — | — |
| Income tax | $0 | $0 | — | $0 | $0 | $0 | — | — |
| Net income | $645,416 | -$1.91M | -$382,021 | -$7.55M | -$1.48M | -$1.41M | -$690,594 | -$3.74M |
| EBITDA | -$513,497 | -$360,359 | -$666,535 | — | -$935,646 | -$840,980 | -$659,076 | -$1.62M |
| EPS (basic) | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 1.27B | 682.48M | 669.79M | — | 662.50M | 662.50M | 662.50M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $32,037 | $555 | $633 | $1,804 | $927 | $16,975 | $1,208 | $2,156 |
| Receivables | $0 | $6,811 | $6,944 | $164,430 | — | — | — | $1,747 |
| Inventory | $1.70M | $1.31M | $902,913 | $1.12M | $863,807 | $1.04M | $951,136 | $996,250 |
| Current assets | $1.74M | $1.33M | $929,554 | $1.31M | $1.47M | $1.20M | $1.24M | $1.02M |
| PP&E, net | $194,651 | $200,461 | $176,101 | $127,029 | $123,333 | $129,389 | $130,077 | $137,237 |
| Total assets | $7.29M | $6.89M | $6.58M | $7.02M | $11.62M | $11.47M | $11.23M | $10.84M |
| Current liabilities | $32.67M | $32.57M | $31.49M | $31.59M | $28.48M | $28.95M | $26.89M | $25.75M |
| Total liabilities | $37.47M | $37.72M | $36.85M | $37.17M | $34.13M | $34.05M | $31.74M | $30.65M |
| Shareholders' equity | -$30.19M | -$30.83M | -$30.27M | -$30.15M | -$22.52M | -$22.57M | -$20.51M | -$19.81M |
| Shares outstanding | 708.69M | 708.69M | 678.50M | 662.50M | 662.50M | 662.50M | 662.50M | 662.50M |
| Cash flow statement | ||||||||
| Operating cash flow | -$166,650 | -$127,369 | -$243,656 | $1.06M | -$802,700 | -$446,463 | -$601,381 | -$179,890 |
| Capital expenditure | $588 | — | — | $5,519 | $0 | — | — | $0 |
| Free cash flow | -$167,238 | — | — | $1.06M | -$802,700 | — | — | -$179,890 |
| Investing cash flow | -$588 | — | — | $794,269 | $0 | — | — | $0 |
| Financing cash flow | $199,175 | $182,409 | $242,485 | -$1.85M | $786,652 | $462,230 | $600,433 | $175,047 |
| Depreciation & amortization | $19,446 | $18,472 | $15,808 | — | $0 | $0 | $18,509 | -$87,278 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.